These preliminary findings have paved the way toward a number of studies assessing ICIs combined with PARPi in several malignancies since PARP inhibition has been suggested to increase tumor mutational burden, augmenting DNA damage processes and upregulating PD-L1 expression. Here, PARP1 is linked to neoplasm.